ERBB2 and colorectal cancer: Given that HER2‐positive colorectal cancer, such as in this case, a rare subtype, accounts for 2%–3% of colorectal cancers, and is associated with a poor response to anti‐epidermal growth factor receptor antibody therapy, targeted treatment options must be considered [10].